Novelion Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference
January 04 2017 - 9:20AM
Novelion Therapeutics, Inc. (NASDAQ:NVLN), a biopharmaceutical
company dedicated to developing new standards of care for
individuals living with rare diseases, announced today that the
company will participate in the 35th Annual J.P. Morgan Healthcare
Conference in San Francisco. Chief Executive Officer Mary Szela is
scheduled to present on Wednesday, January 11, 2017 at 4:00 p.m.
PST (7:00 p.m. EST).
The presentation will be webcast live and may be accessed for up
to 30 days following the conference by visiting the “Investors”
section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics Novelion
Therapeutics is a biopharmaceutical company dedicated to developing
new standards of care for individuals living with rare diseases.
The company seeks to advance its portfolio of rare disease
therapies by investing in science and clinical development.
Novelion has a diversified commercial portfolio through its
indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes
MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate
for the treatment of inherited retinal disease caused by underlying
mutations in RPE65 or LRAT genes.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
Amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024